Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study out on JITC buff.ly/iFnRFbO This retrospective, multicenter study examined the safety and clinical outcomes of 110 patients with solid tumors and cardiac metastasis treated with immune checkpoint inhibitors (ICIs). The most common cancers were #melanoma (38%) and non-small cell lung cancer #NSCLC (24%), with cardiac metastases frequently located in the atria and ventricles. Cardiac events occurred in 36% of patients, but ICI-related major cardiac adverse events were rare (1.8%). Treatment-related adverse events (trAEs) were common, with 20% experiencing severe (grade ≥3) trAEs. Patients with multiple cardiac metastases had lower response rates to ICI-based therapies. Overall, ICIs showed meaningful efficacy, particularly in melanoma, with no increase in safety risks, highlighting the importance of multidisciplinary management in these complex cases. @AminNassarMD @sarahaboualaiwi @TalalZarif1 @RyanDenu @WNMacaron @Dory_Freeman @Avasbind @salimhayek @ShirlyGrynberg @jennkwanMDPhD @ProfGLongMIA @TarekHaykal1 @Atandondoc @nakhtermd @datsunian @EdwardElAmm @eliekozaily1 @ahmadalhader @boufarhat_elias @mer_herreraMD @chulkimMD @kaushalpar @ADesaiMD @ACortelliniMD @DJPinato @JamesKz_ @nerealiamd @FunchainMD @AChoudharyMD @AartiAsnaniMD @navstruck @ja_ocejo @JTrentMDPhD @DrRanaMcKay @TomasNeilan @DrChoueiri @thenasheffect